医学
安慰剂
结直肠癌
内科学
临床终点
化疗
随机对照试验
不利影响
阶段(地层学)
肿瘤科
疾病
外科
置信区间
临床研究阶段
胃肠病学
癌症
放射性武器
原发性肿瘤
临床试验
切除术
作者
Hideaki Bando,Jun Watanabe,Yusuke Takahashi,Masahito Kotaka,Nobuhisa Matsuhashi,Eiji Oki,Yoshito Komatsu,Manabu Shiozawa,Keiji Hirata,Y Miyamoto,Masanobu Takahashi,Kentaro Yamazaki,Dai Manaka,Akiyoshi Kanazawa,Yi-Hsin Liang,Kun‐Huei Yeh,Yuko Watsuji,Yuko Yamamoto,Makoto Fukui,Shruti Sharma
标识
DOI:10.1038/s41591-026-04428-0
摘要
Tumor-informed circulating tumor DNA (ctDNA) enables detection of molecular residual disease (MRD) after curative resection of colorectal cancer (CRC), but whether early intervention improves outcomes remains uncertain. ALTAIR was a randomized, double-blind, phase 3 trial embedded in the CIRCULATE-Japan platform evaluating a post-adjuvant ctDNA surveillance strategy with treatment initiation upon molecular recurrence. Patients with resected stage 0–IV CRC who became ctDNA positive after completion of standard-of-care therapy and had no radiological evidence of disease were randomly assigned (1:1) to receive trifluridine/tipiracil (FTD/TPI) or placebo for 6 months. The primary endpoint was investigator-assessed disease-free survival (DFS). Between July 2020 and June 2023, 243 patients were randomized to FTD/TPI (n = 122) or placebo (n = 121). Median DFS was 9.30 months with FTD/TPI and 5.55 months with placebo (hazard ratio = 0.79, 95% confidence interval: 0.60–1.05, P = 0.107), and the primary endpoint was not met. FTD/TPI increased grade 3 or higher hematologic adverse events (73.0% versus 3.3%) without new safety signals. These findings indicate that post-adjuvant intervention with FTD/TPI did not significantly improve DFS in ctDNA-positive patients without radiological disease. ClinicalTrials.gov identifier: NCT04457297 . In the randomized, double-blind phase 3 ALTAIR trial, patients with resected colorectal cancer who became positive for circulating tumor DNA during post-adjuvant surveillance received trifluridine/tipiracil hydrochloride therapy, which did not significantly prolong disease-free survival compared with placebo.
科研通智能强力驱动
Strongly Powered by AbleSci AI